金河生物(002688.SZ):三名實控人、董事、高管減持期過半 合計減持80萬股
格隆匯8月24日丨金河生物(002688.SZ)公佈,公司於2020年8月24日收到公司副董事長李福忠,實際控制人、董事、副總經理王志軍和實際控制人王曉英出具的《股東減持計劃進展告知函》,獲悉李福忠、王志軍和王曉英以集中競價交易方式減持股份時間已過半。
其中,李福忠通過集中競價方式減持公司股份60萬股,佔公司總股本的0.0944%;王曉英通過集中競價方式減持公司股份20萬股,佔公司總股本的0.0314%;王志軍尚未減持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.